Diagnosis and management of AML in adults : 2022 recommendations from an international expert panel on behalf of the ELN
Döhner, Hartmut (Ulm University Hospital. Department of Internal Medicine III)
Wei, Andrew H. (Peter MacCallum Cancer Centre. Royal Melbourne Hospital and University of Melbourne. Department of Haematology)
Appelbaum, Frederick (University of Washington. Fred Hutchinson Cancer Research Center)
Craddock, Charles (Centre for Clinical Haematology. Queen Elizabeth Hospital. University of Birminham)
DiNardo, Courtney D. (The University of Texas MD Anderson Cancer Center. Department of Leukemia)
Dombret, Hervé (Saint-Louis Institute for Research. Université de Paris. Hôpital Saint-Louis. Assistance Publique-Hôpitaux de Paris. Department of Hematology)
Ebert, Benjamin L. (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica))
Fenaux, Pierre (Hôpital Saint-Louis (París, França))
Godley, Lucy A. (The University of Chicago. Section of Hematology/Oncology. Department of Medicine)
Hasserjian, Robert P (Massachusetts General Hospital (Boston))
Larson, Richard A (University of Chicago. Department of Medicine and Comprehensive Cancer Center)
Levine, Ross L. (Memorial Sloan Kettering Cancer Center)
Miyazaki, Yasushi (Atomic Bomb Disease Institute. Nagasaki University. Department of Hematology)
Niederwieser, Dietger (University of Leipzig)
Ossenkoppele, Gert (Amsterdam University Medical Center (UMC))
Röllig, Christoph (Department of Internal Medicine I. University Hospital Carl Gustav Carus TU Dresden)
Sierra, Jorge (Institut d'Investigació Biomèdica Sant Pau)
Stein, Eytan M. (Memorial Sloan Kettering Cancer Center)
Tallman, Martin S. (Memorial Sloan Kettering Cancer Center)
Tien, Hwei-Fang F. (Division of Hematology. Department of Internal Medicine. National Taiwan University Hospital)
Wang, Jianxiang (Institute of Hematology and Blood Diseases Hospital. Chinese Academy of Medical Sciences & Peking Union Medical College)
Wierzbowska, Agnieszka (Department of Hematology. Medical University of Lodz)
Löwenberg, Bob (Department of Hematology. Erasmus University Medical Center Rotterdam and Erasmus MC Cancer Institute)

Date:	2022
Abstract:	The 2010 and 2017 editions of the European LeukemiaNet (ELN) recommendations for diagnosis and management of acute myeloid leukemia (AML) in adults are widely recognized among physicians and investigators. There have been major advances in our understanding of AML, including new knowledge about the molecular pathogenesis of AML, leading to an update of the disease classification, technological progress in genomic diagnostics and assessment of measurable residual disease, and the successful development of new therapeutic agents, such as FLT3, IDH1, IDH2, and BCL2 inhibitors. These advances have prompted this update that includes a revised ELN genetic risk classification, revised response criteria, and treatment recommendations.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Subject:	Adult ; Antineoplastic Agents ; Humans ; Leukemia, Myeloid, Acute ; Mutation ; Neoplasm, Residual ; Nucleophosmin ; Prognosis ; Proto-Oncogene Proteins c-bcl-2
Published in:	Blood, Vol. 140 Núm. 12 (september 2022) , p. 1345-1377, ISSN 1528-0020

DOI: 10.1182/blood.2022016867
PMID: 35797463

33 p, 2.0 MB

The record appears in these collections:
Research literature > UAB research groups literature > Research Centres and Groups (research output) > Health sciences and biosciences > Institut de Recerca Sant Pau
Articles > Research articles
Articles > Published articles